This white paper, developed in collaboration with our founder, Dr. Kenneth Rockwood, establishes the compelling value of Goal Attainment Scaling (GAS) as a personalized outcome assessment within clinical drug development programs. GAS addresses key limitations of traditional endpoints by quantifying treatment effects on individualized, patient-meaningful goals. Drawing on case studies from Alzheimer’s disease (the VISTA and ACADIE trials) in Canada, the paper demonstrates how GAS data played a pivotal role in both securing and shaping drug reimbursement decisions. By directly informing HTA evaluations, GAS helped expand patient access and validate the real-world value of the interventions.